Aduro BioTech is a clinical-stage immunotherapy company developing novel and potent vaccines based on Listeria monocytogenes. The company has
engineered two distinct Listeria vaccine platforms to be safe for use in humans while continuing to induce robust immune responses. These advances
have been published in 20 major studies and have generated more than $20 million in grant funding.
|
See the article on Aduro from the San Francisco Business Times.
Aduro BioTech announces key milestones in advancing its leading Listeria-based immunotherapy program. Read it here.
|